ArticleACS biomaterials science & engineering2019
Dual-Sized Microparticle System for Generating Suppressive Dendritic Cells Prevents and Reverses Type 1 Diabetes in the Nonobese Diabetic Mouse Model.
Article in ACS biomaterials science & engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 78 citations in OpenAlex.
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Dendritic Cells as Immunometabolic Regulatory Nodes in Diabetes: Molecular Mechanisms and Therapeutic Reprogramming.International journal of molecular sciences · 2026Review
- Tunable wrinkled topographies direct dendritic cell maturation and immune phenotypes.Acta biomaterialia · 2026Article
- Antigen-Specific Inverse Vaccination Strategies Using Particle Systems for Multiple Sclerosis.ACS biomaterials science & engineering · 2026Review
- Article
- Sustained microparticle-mediated intracellular immunomodulation enhances tolerogenic dendritic cell stability and antigen-specific Treg induction.Frontiers in immunology · 2026Article
- Innovative polymer-based therapeutics targeting inflammation for responsive drug delivery in disease treatment.Inflammopharmacology · 2025Review
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Anionic lipids modulate mRNA-lipid nanoparticle immunogenicity and confer protection in a mouse model of multiple sclerosis.bioRxiv : the preprint server for biology · 2025Article
- Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases.Molecular therapy. Methods & clinical development · 2025Review
- Review
- Synthetic organic materials for targeting immunotherapies to lymph nodes.Chemistry of materials : a publication of the American Chemical Society · 2024Article
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- Engineering antigen-presenting cells for immunotherapy of autoimmunity.Advanced drug delivery reviews · 2024Review
- Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment.Bioactive materials · 2024Review
- Therapeutic induction of antigen-specific immune tolerance.Nature reviews. Immunology · 2024Review
- ABCD of IA: A multi-scale agent-based model of T cell activation in inflammatory arthritis.Biomaterials science · 2024Article
- A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action.Frontiers in immunology · 2024Review
- Antigen-specific T cell responses in autoimmune diabetes.Frontiers in immunology · 2024Review
- Epitope-based precision immunotherapy of Type 1 diabetes.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Antigen specificity is a primary goal in developing curative therapies for autoimmune disease. Dendritic cells (DCs), as the most effective antigen presenting cells in the body, represent a key target to mediate restoration of antigen-specific immune regulation. Here, we describe an injectable, dual-sized microparticle (MP) approach that employs phagocytosable ∼1 μm and nonphagocytosable ∼30 μm MPs to deliver tolerance-promoting factors both intracellularly and extracellularly, as well as the type 1 diabetes autoantigen, insulin, to DCs for reprogramming of immune responses and remediation of autoimmunity. This poly(lactic-
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.